Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

MONTVALE, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today reported net earnings of $128.4 million, or $1.18 per share, for the year ended December 31, 2007 on revenues of $2.5 billion. On a non-GAAP basis, adjusted earnings per share were $3.16 for 2007. A reconciliation of GAAP-based earnings per share to adjusted earnings per share is presented in the table at the end of this press release. For the fourth quarter ended December 31, 2007, net earnings were $32.5 million, or $0.30 per share, on revenues of $668.7 million. On a non-GAAP basis, adjusted earnings per share were $0.79 for the quarter.

In the fourth quarter of calendar 2006, Barr changed its fiscal year end from June 30th to December 31st, effective December 31, 2006. In addition, on October 24, 2006, Barr acquired PLIVA d.d., a Croatian generics pharmaceutical company, for approximately $2.4 billion. As a result of these two events, the comparison of information for the year ended December 31, 2007 and the 12- month period ended December 31, 2006, which is unaudited, is not very meaningful. In this release, "2007" refers to Barr's calendar year ended December 31, 2007, and "2006" refers to the 12-month period ended December 31, 2006 and includes PLIVA's results from October 25, 2006 through December 31, 2006.

"I am pleased to report strong revenue growth across the Company in 2007, driven by proprietary and U.S. generic sales, as well as sound results in our international markets. In addition, during the year we invested a record $248 million in new product development, and filed a record 30 ANDAs and three NDAs in the United States. These are exceptional results for our Company, particularly given that significant management
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... (PRWEB) November 21, 2014 Two new educational ... what comes next for ALS research and how the pharmaceutical ... After the Ice Bucket Challenge: Where Does the ALS Money ... Tuesday, 2 December 2014, Time: 1:30pm ET, Register ... expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology ...
(Date:11/22/2014)... 2014 Prominent academics, leaders of ... on December 3rd at Genetic Rx, a networking ... will take place at the Joseph B. Martin ... discuss the present and future of genetic medicines—including ... gene editing—as well as the treatment of patients ...
(Date:11/22/2014)... 2014 RURO, Inc., a leading ... released Limfinity® version 5.1.4. , RURO’s deployment teams ... than ever in RURO’s 8 year history. Many ... enhancement. Limfinity® version 5.1.4 is the perfect example ... bug fixes! , Limfinity® 5.1.4 release highlights – ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by ... Glass, Plastic), by Application [GC, LC (HPLC, UHPLC, ... 2018” analyses and studies the major market drivers, ... Asia, and Rest of the World. , Browse ... through 135 pages and in-depth TOC on “Chiral ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... a Techne Corporation (Nasdaq: TECH ) Director and ... and Governance Committee, announced today that he is planning to ... 29, 2009. Techne,s shareholders reelect Directors on an annual ... for re-nomination as a Director for fiscal year 2010.Mr. Herbert ...
... PALO ALTO, Calif., May 19 Pioneering ... has secured clearance from the U.S. Food ... personal ultrasound device, the ,Signos,.(Photo: http://www.newscom.com/cgi-bin/prnh/20090519/SF19276 ... for the first time makes it affordable ...
... Mode of ActionMOUNTAIN VIEW, Calif., May 19 ... from the company,s PROTECT-1 (the Prospective Randomized Oral ... clinical trial of Traficet-EN(TM) (CCX282-B) in patients with ... oral session at the upcoming 2009 Digestive Disease ...
Cached Biology Technology:Techne Corporation Announces the Retirement of G. Arthur Herbert, a Member of Its Board of Directors 2Signostics Receives FDA Clearance for World's Smallest Ultrasound Product 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... most common sensory disorder among the elderly. But scientists are ... contribute to the loss. Now a University of Florida ... institutions have identified a protein that is central to processes ... hearing loss. The findings help point the way toward ...
... by the U.S. Food and Drug Administration in patients ... invasiveness of ovarian cancer cells and also promoted their ... Cancer Center found. The drug, when paired with ... ovarian cancer in cell lines in which signaling of ...
... blooms of tiny marine plants called phytoplankton are flourishing in ... rapid melting of ice shelves and glaciers around the Antarctic ... climate change. As the blooms die back phytoplankton sinks to ... millions of years. Reporting this week in the ...
Cached Biology News:'Escaped' proteins add to hearing loss in elderly, UF researchers find 2'Escaped' proteins add to hearing loss in elderly, UF researchers find 3FDA approved leukemia drugs shows promise in ovarian cancer cells 2Antarctica glacier retreat creates new carbon dioxide store 2
... monoclonal antibody raised against a partial recombinant IFNA2. ... a.a.) partial recombinant protein is produced in E. ... 8 IU/ mg. OMIM: ... Lot Number: MM951100564 MA ...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
...
Biology Products: